CSL Ltd Annual Report 2021

Paul McKenzie PhD (Chemical Engineering) Age 54 Chief Operating Officer Paul was appointed Chief Operating Officer in June 2019 and leads CSL’s global end-to-end operations organisation and its accompanying strategy. He has responsibility for manufacturing, quality, engineering, supply chain, procurement and environment, health and safety, as well as CSL Plasma and its network of collection centres in the US, China and Europe. Paul also has responsibility for Seqirus. Prior to joining CSL, Paul served as executive vice president of Pharmaceutical Operations and Technology at Biogen. With more than 25 years of experience, Paul held various senior roles in research and development and manufacturing for Johnson & Johnson, Bristol-Myers Squibb and Merck & Co. Paul holds a Bachelor of Science degree in Chemical Engineering from the University of Pennsylvania and a PhD in Chemical Engineering from Carnegie Mellon University. He was elected to the National Academy of Engineering in 2020. Bill Mezzanotte MD, MPH Age 62 Executive Vice President, Head Research & Development and Chief Medical Officer Bill was appointed Head of Research & Development (R&D) in October 2018 and assumed the role of Chief Medical Officer in 2020. He is responsible for developing and executing CSL’s R&D strategy and portfolio, including the identification and development of all R&D platforms, skills and expertise necessary for success. Bill initially joined CSL as head of clinical development in 2017. Prior to CSL, Bill was senior vice president and therapeutic area head for the respiratory unit for Boehringer Ingelheim and spent 16 years with AstraZeneca in research and development, assuming roles of increasing leadership and management responsibility across multiple therapeutic areas. Bill obtained his MD at the University of Pennsylvania and a Master of Public Health degree from Johns Hopkins University. He is board certified in internal medicine, pulmonary medicine, critical care medicine and sleep medicine and currently serves as a member of the Board of Directors of the Philadelphia- based University City Science Center. Elizabeth Walker BA, MS (Organisational Development and Leadership) Age 51 Executive Vice President, Chief Human Resources Officer Elizabeth was appointed Chief Human Resources Officer in December 2017. She joined CSL Behring as chief talent officer in 2016 and served as interim chief human resources officer fromOctober 2017. Prior to joining CSL, Elizabeth was vice president Global Talent Management at Campbell Soup Company. She has more than 25 years’ experience in both management consulting and human resources. Elizabeth has worked across a variety of industries, including healthcare, financial services and food manufacturing. Alan Wills BA (Zoology), MBA Age 57 Executive Vice President, Strategy and Business Development Alan joined the company in February 2015. He is responsible for strategy, portfolio management and business development activities at CSL. Prior to joining CSL, Alan was executive vice president, corporate development at Auxilium Pharmaceuticals. He was previously head of corporate strategy for Bristol-Myers Squibb and Pfizer, and has worked in strategy and business development roles at United Healthcare and Stanford Medical Center. Alan began his career with the Boston Consulting Group. On 1 October 2020, CSL announced the appointment of Joy Linton to replace David Lamont as the Chief Financial Officer who left CSL on 30 October 2020. Other leadership changes during the financial year include Mark Hill, Chief Digital Officer, joining CSL and the Global Leadership Group. More on CSL.com (Our Company > Board and Management) CSL Limited Annual Report 2020/21 65